FDAMA Reporting Activities

• Report to Congress not later than 1/1/2001

  • Effectiveness of program in improving information about important pediatric uses for approved drugs
  • Adequacy of the incentive
  • The economic impact of the program on taxpayers and consumers, including the impact on the lack of lower cost generic drugs on patients, including on lower income patients…
  • Any suggestions for modification

Previous slide

Next slide

Back to first slide

View graphic version